What's new? Log in Free sign up

Filing search / Butterfly Network, Inc. / "Investigation"

Search information

Butterfly Network, Inc.

Companies

"Investigation"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

73 results

Newest first Best match first

BFLY Butterfly Network, Inc.

penalties. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond … to IP or other proprietary information, litigation, investigation, and possible liability to employees, customers, suppliers, patients, and regulatory

4 Mar 24

7:00am

BFLY Butterfly Network, Inc.

Prospectus update (post-effective amendment)

through focused clinical trials. In order to conduct a clinical investigation involving human subjects for the purpose of demonstrating the safety … other things, apply for and obtain institutional review board (“IRB”) approval of the proposed investigation. In addition, if the clinical study

BFLY Butterfly Network, Inc.

Shelf registration

investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order … by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the security afforded

BFLY Butterfly Network, Inc.

Shelf registration

or rights or powers conferred upon it by this Indenture; (f) The Trustee shall not be bound to make any investigation into the facts or matters stated … a reasonable time to the Trustee of the costs, expenses, claims or liabilities likely to be incurred by it in the making of such investigation

BFLY Butterfly Network, Inc.

Prospectus update (post-effective amendment)

or services, we anticipate that we will need to validate at-home applications through focused clinical trials. In order to conduct a clinical investigation … ”) approval of the proposed investigation. In addition, if the clinical study involves a “significant risk” (as defined by the FDA) to human health

Prospectus supplement

Prospectus update (post-effective amendment)

Annual report (amended)

19 Apr 22

5:26pm

Results of Operations and Financial Condition

Departure of Directors or Certain Officers

Entry into a Material Definitive Agreement

Quarterly report (amended)

28 Mar 22

6:12am

Quarterly report (amended)

28 Mar 22

6:08am

Annual report (amended)

25 Mar 22

9:53pm

28 Feb 22

5:19pm

Prospectus supplement

km1rrothh1nrqrqa 3f

Results of Operations and Financial Condition

Prospectus supplement

o7q2j5x0w08qw 1il5u

Quarterly report

15 Nov 21

12:00am

Prospectus supplement

Prev
1
2
3
4
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.